[1]何金龙.两种不同干预策略在射血分数降低心力衰竭患者中的应用效果[J].医学信息,2022,35(18):48-52.[doi:10.3969/j.issn.1006-1959.2022.18.011]
 HE Jin-long.Application Effect of Two Different Intervention Strategies in Heart Failure Patients with Heart Failure with Reduced Ejection Fraction[J].Journal of Medical Information,2022,35(18):48-52.[doi:10.3969/j.issn.1006-1959.2022.18.011]
点击复制

两种不同干预策略在射血分数降低心力衰竭患者中的应用效果()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
48-52
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Application Effect of Two Different Intervention Strategies in Heart Failure Patients with Heart Failure with Reduced Ejection Fraction
文章编号:
1006-1959(2022)18-0048-05
作者:
何金龙
(广西中医药大学附属瑞康医院心血管内科,广西 南宁 530000)
Author(s):
HE Jin-long
(Department of Cardiovascular Internal Medicine,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530000,Guangxi,China)
关键词:
射血分数降低慢性心力衰竭血流动力学心功能
Keywords:
Heart failure with reduced ejection fractionHemodynamicsCardiac function
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2022.18.011
文献标志码:
A
摘要:
目的 比较两种不同干预策略在射血分数降低心力衰竭(HFrEF)患者中的应用效果。方法 选择2021年4月-2022年4月广西中医药大学附属瑞康医院住院治疗的HFrEF患者80例作为研究对象,按临床干预策略不同分为新流程组和传统流程组,每组40例。新流程组在4周内按照SGLT2i+β阻滞剂、ARNI、MRA序贯给药,然后逐步滴定到靶剂量;而传统流程组按照血管紧张素转换酶抑制剂/血管紧张素转化酶(ACEI/ARB)、β阻滞剂、MRA、ARNI、SGLT2i序贯给药。比较两组干预后4、12周血流动力学变化、心功能变化、生活质量相关参数。结果 两组治疗后4、12周SBP、LVEF高于治疗前,HR、LVD低于治疗前,且治疗后12周新流程组SBP、LVEF高于传统流程组,HR、LVD低于传统流程组,差异有统计学意义(P<0.05);两组治疗后4、12周6 min步行距离、VO2max高于治疗前,LiHFe评分低于治疗前,且治疗后4、12周新流程组6 min步行距离高于传统流程组,LiHFe评分低于传统流程组,差异有统计学意义(P<0.05),而治疗后12周新流程组VO2max高于传统流程组,差异有统计学意义(P<0.05)。结论 CHF治疗过程中,特别是12周的优化药物治疗流程可改善HFrEF患者的血流动力学及生活质量,提高左室射血分数并逆转心肌重构,具有临床应用价值。
Abstract:
Objective To compare the effects of two different intervention strategies in patients with heart failure with reduced ejection fraction (HFrEF).Methods A total of 80 patients with HFrEF who were hospitalized in Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine from April 2021 to April 2022 were selected as the research objects. According to different clinical intervention strategies, they were divided into new process group and traditional process group, with 40 cases in each group. The new process group was administered sequentially according to SGLT2i+β blocker, ARNI, MRA within 4 weeks, and then gradually titrated to the target dose. The traditional process group was administered sequentially according to the angiotensin converting enzyme inhibitor/angiotensin converting enzyme (ACEI/ARB), β blocker, MRA, ARNI, SGLT2i. Hemodynamic changes, cardiac function changes and quality of life related parameters were compared between the two groups at 4 and 12 weeks after intervention.Results At 4 and 12 weeks after treatment, SBP and LVEF of the two groups were higher than those before treatment, and HR and LVD were lower than those before treatment; at 12 weeks after treatment, SBP and LVEF of the new process group were higher than those of the traditional process group, and HR and LVD were lower than those of the traditional process group, and the differences were statistically significant (P<0.05). At 4 and 12 weeks after treatment, the 6-min walking distance and VO2max of the two groups were higher than those before treatment, and the LiHFe score was lower than that before treatment; the 6-min walking distance of the new process group was higher than that of the traditional process group at 4 and 12 weeks after treatment, and the LiHFe score was lower than that of the traditional process group, and the differences were statistically significant (P<0.05); the VO2max of the new process group was higher than that of the traditional process group at 12 weeks after treatment, and the differences were statistically significant (P<0.05).Conclusion In the course of CHF treatment, especially 12 weeks of optimized drug treatment process can improve the hemodynamics and quality of life of patients with HFrEF, increase the left ventricular ejection fraction and reverse myocardial remodeling, which has clinical application value.

参考文献/References:

[1]Pontremoli R,Borghi C,Perrone Filardi P.Renal protection in chronic heart failure: focus on sacubitril/valsartan[J].Eur Heart J Cardiovasc Pharmacother,2021,7(5):445-452.[2]McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726.[3]Ben Gal T,Ben Avraham B,Milicic D,et al.Guidance on the management of left ventricular assist device(LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary[J].Eur J Heart Fail,2021,23(10):1597-1609.[4]Chera HH,Al-Sadawi M,Michelakis N,et al.Optimizer Smart System for the treatment of chronic heart failure: Overview of its safety and efficacy[J].Expert Rev Med Devices,2021,18(6):505-512.[5]Mogensen UM,K?覬ber L,S?覬ren L,et al.The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF[J].American Heart Journal,2017,188:35-41.[6]Balmforth C,Simpson J,Shen L,et al.Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF[J].J Am Coll Cardiol Heart Fail,2019,7(6)457-465.[7]Vaduganathan M,Claggett B,Jhund P,et al.Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials[J].Lancet,2020,396(10244):121-128.[8]McMurray JJ,Packer M.How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine[J].Circulation.2021,143:875-877.[9]Yeoh SE,Dewan P,Serenelli M,et al.Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES[J].Eur J Heart Fail,2022,24(3):529-538.[10]Catchpool M,Ramchand J,Hare DL,et al.Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scores[J].Qual Life Res,2020,29(10):2815-2822.[11]Kusuma DY,Shatri H,Alwi I,et al.Validity and Reliability Studies of the Indonesian Version of the MinnesotaLiving with Heart Failure Questionnaire (MLHFQ):Quality of Life Questionnaire for Patients with Chronic Heart Failure[J].Acta Med Indones,2019,51(1):26-33.[12]Mapelli M,Salvioni E,Paneroni M,et al.Brisk walking can be a maximal effort in heart failure patients: a comparison of cardiopulmonary exercise and 6 min walking test cardiorespiratory data[J].ESC Heart Fail,2022,9(2):812-821.[13]Lancaster L,Fieuw A,Meulemans J,et al.Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis[J].Contemp Clin Trials,2021,100:106227.[14]Kinoshita H,Sairaku A,Morishima N,et al.Prognostic significance of oscillatory ventilation at rest in patients with advanced heart failure undergoing cardiopulmonary exercise testing[J].Int J Cardiol,2020,301:142-146.[15]Pryor JL,Leija RG,Morales J,Potter AW,et al.Verification Testing to Confirm VO2max in a Hot Environment[J].Med Sci Sports Exerc,2021,53(4):763-769.[16]Wang R,Zhang Z,Xu Z,et al.Gastrin mediates cardioprotection through angiogenesis after myocardial infarction by activating the HIF-1α/VEGF signalling pathway[J].Sci Rep,2021,11(1):15836.[17]Chen F,Tian G,Bai X,et al.The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction[J].Ann Palliat Med,2021,10(8):8684-8691.[18]Fu J,Tang Y,Zhang Z,et al.Gastrin exerts a protective effect against myocardial infarction via promoting angiogenesis[J].Mol Med,2021,27(1):90.[19]Bao J,Kan R,Chen J,et al.Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction:A systematic review and network meta-analysis of randomized clinical trials[J].Pharmacol Res,2021,169:105573.[20]Mc Donagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726.[21]Heidenreich PA,Bozkurt B,Aguilar D,et al.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2022,145(18):e895-e1032.[22]Ahn MS,Yoo BS,Son JW,et al.Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation[J].J Korean Med Sci,2021,36(40):e252.[23]Ferreira JP,Anker SD,Butler J,et al.Impact of anaemia and the effect of empagliflozin in?heart failure with reducedejection fraction: findings from EMPEROR-Reduced[J].Eur J Heart Fail,2022,24(4):708-715.[24]Carnicelli AP,Li Z,Greiner MA,et al.Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction[J].JACC Heart Fail,2021,9(12):876-886.[25]Shen L,Jhund PS,Docherty KF,et al.Accelerated and personalized therapy for heart failure with reduced ejection fraction[J].Eur Heart J,2022,43(27):2573-2587.

相似文献/References:

[1]袁 曦.罗库溴铵与七氟烷用于气管插管的麻醉效果对比分析[J].医学信息,2018,31(12):136.[doi:10.3969/j.issn.1006-1959.2018.12.042]
 YUAN Xi.Comparative Analysis of Anesthetic Effects of Rocuronium and Sevoflurane in Tracheal Intubation[J].Journal of Medical Information,2018,31(18):136.[doi:10.3969/j.issn.1006-1959.2018.12.042]
[2]刘 亮,韩建阁.右美托咪定在心血管手术麻醉中的应用[J].医学信息,2022,35(11):60.[doi:10.3969/j.issn.1006-1959.2022.11.017]
 LIU Liang,HAN Jian-ge.Application of Dexmedetomidine in Anesthesia of Cardiovascular Surgery[J].Journal of Medical Information,2022,35(18):60.[doi:10.3969/j.issn.1006-1959.2022.11.017]
[3]李树贤,李 倩.宫腔镜手术麻醉中应用右美托咪定与瑞芬太尼复合依托咪酯的效果比较[J].医学信息,2022,35(11):114.[doi:10.3969/j.issn.1006-1959.2022.11.029]
 LI Shu-xian,LI Qian.Comparison of the Effect of Dexmedetomidine and Remifentanil Combined with Etomidate in Hysteroscopic Surgery Anesthesia[J].Journal of Medical Information,2022,35(18):114.[doi:10.3969/j.issn.1006-1959.2022.11.029]
[4]马兴对,吴 靓,姬宁宁,等.喉罩替换气管导管在开颅手术苏醒期中的应用研究[J].医学信息,2018,31(23):91.[doi:10.3969/j.issn.1006-1959.2018.23.025]
 MA Xing-dui,WU Liang,JI Ning-ning,et al.Observation on the Effect of Laryngeal Mask Replacement Tracheal Tube in the Period of Extubation in Craniotomy[J].Journal of Medical Information,2018,31(18):91.[doi:10.3969/j.issn.1006-1959.2018.23.025]
[5]马孝天,余书康,李贯清.H型高血压与腔隙性脑梗死患者血流动力学变化的相关研究[J].医学信息,2018,31(24):78.[doi:10.3969/j.issn.1006-1959.2018.24.020]
 MA Xiao-tian,YU Shu-kang,LI Guan-qing.Correlation between Hemodynamic Changes in Patients with H-type Hypertension and Lacunar Infarction[J].Journal of Medical Information,2018,31(18):78.[doi:10.3969/j.issn.1006-1959.2018.24.020]
[6]王国粉,王繁静,马 滨,等.右美托咪定对脓毒症休克患者围术期血流动力学、乳酸清除率的影响[J].医学信息,2022,35(12):153.[doi:10.3969/j.issn.1006-1959.2022.12.037]
 WANG Guo-fen,WANG Fan-jing,MA Bin,et al.Effect of Dexmedetomidine on Perioperative Hemodynamics and Lactate Clearance Rate in Patients with Septic Shock[J].Journal of Medical Information,2022,35(18):153.[doi:10.3969/j.issn.1006-1959.2022.12.037]
[7]赵 悦,董 婕,韩晨阳,等.Bioz.com用于心脏手术围术期监测的临床价值研究[J].医学信息,2019,32(05):108.[doi:10.3969/j.issn.1006-1959.2019.05.033]
 ZHAO Yue,DONG Jie,HAN Chen-yang,et al.Clinical Value Study of Bioz.com for Perioperative Monitoring of Cardiac Surgery[J].Journal of Medical Information,2019,32(18):108.[doi:10.3969/j.issn.1006-1959.2019.05.033]
[8]刘世强,邓津津,王 卫.心脏超声对急性心肌梗死心脏功能指标评价的研究[J].医学信息,2022,35(14):180.[doi:10.3969/j.issn.1006-1959.2022.14.047]
 LIU Shi-qiang,DENG Jin-jin,WANG Wei.Evaluation of Cardiac Function Indexes of Acute Myocardial Infarction by Echocardiogram[J].Journal of Medical Information,2022,35(18):180.[doi:10.3969/j.issn.1006-1959.2022.14.047]
[9]芦树军,刘云霞,喻文立,等.先天性胆道闭锁合并卵圆孔未闭患儿肝移植围术期血流动力学及心功能变化[J].医学信息,2019,32(20):95.[doi:10.3969/j.issn.1006-1959.2019.20.026]
 LU Shu-jun,LIU Yun-xia,YU Wen-li,et al.Changes of Hemodynamics and Cardiac Function During Liver Transplantation Period in Children with Congenital Biliary Atresia with Patent Foramen Ovale[J].Journal of Medical Information,2019,32(18):95.[doi:10.3969/j.issn.1006-1959.2019.20.026]
[10]刘忠涛.罗哌卡因复合亚甲蓝椎旁阻滞对胸腔镜肺段切除术患者血流动力学及术后镇痛的影响[J].医学信息,2022,35(18):44.[doi:10.3969/j.issn.1006-1959.2022.18.010]
 LIU Zhong-tao.Effects of Ropivacaine Combined with Methylene Blue Paravertebral Block on Hemodynamics and Postoperative Analgesia in Patients Undergoing Thoracoscopic Segmentectomy[J].Journal of Medical Information,2022,35(18):44.[doi:10.3969/j.issn.1006-1959.2022.18.010]

更新日期/Last Update: 1900-01-01